Skip to main content

Table 1 Participant characteristics

From: A preliminary clinical trial to evaluate 64Cu-NOTA-Trastuzumab as a positron emission tomography imaging agent in patients with breast cancer

Subject no Age (years) Histology Stage IHC score* (CNB) SISH IHC score (excision) Neoadjuvant chemotherapy History of Trastuzumab treatment Interval from CNB to 64Cu-NOTA-Trastuzumab (months) Tumor size (cm)
1 45 IDC IV 3+  N/A N/A 1 7.3
2 42 IDC IIIB 3+  N/A 3+  AC #3 2 2.4
3 46 IDC IIIA 3+ N/A 1+ AC #4 3 1.7
4 45 IDC IIA N/A AC #4 3 2.2
5 56 IDC IIIB 2+ 1+ AC #4 3 14.0
6 54 IDC IIB N/A AC #3 2 4.6
  1. IHC immunohistochemistry, SISH silver-enhanced in situ hybridization, CNB core needle biopsy, IDC invasive ductal carcinoma, N/A not applicable, AC anthracycline, and cyclophosphamide
  2. *IHC score with core needle biopsy at the initial diagnosis
  3. IHC score with tumor excision after neoadjuvant chemotherapy